199 related articles for article (PubMed ID: 37082578)
1. African American Prostate Cancer Displays Quantitatively Distinct Vitamin D Receptor Cistrome-transcriptome Relationships Regulated by BAZ1A.
Siddappa M; Hussain S; Wani SA; White J; Tang H; Gray JS; Jafari H; Wu HC; Long MD; Elhussin I; Karanam B; Wang H; Morgan R; Hardiman G; Adelani IB; Rotimi SO; Murphy AR; Nonn L; Davis MB; Kittles RA; Hughes Halbert C; Sucheston-Campbell LE; Yates C; Campbell MJ
Cancer Res Commun; 2023 Apr; 3(4):621-639. PubMed ID: 37082578
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of 1α,25-dihydroxyvitamin D3-dependent chromatin accessibility of early vitamin D receptor target genes.
Seuter S; Pehkonen P; Heikkinen S; Carlberg C
Biochim Biophys Acta; 2013 Dec; 1829(12):1266-75. PubMed ID: 24185200
[TBL] [Abstract][Full Text] [Related]
3. Differential gene regulation by a synthetic vitamin D receptor ligand and active vitamin D in human cells.
Iwaki M; Kanemoto Y; Sawada T; Nojiri K; Kurokawa T; Tsutsumi R; Nagasawa K; Kato S
PLoS One; 2023; 18(12):e0295288. PubMed ID: 38091304
[TBL] [Abstract][Full Text] [Related]
4. A hierarchical regulatory network analysis of the vitamin D induced transcriptome reveals novel regulators and complete VDR dependency in monocytes.
Warwick T; Schulz MH; Günther S; Gilsbach R; Neme A; Carlberg C; Brandes RP; Seuter S
Sci Rep; 2021 Mar; 11(1):6518. PubMed ID: 33753848
[TBL] [Abstract][Full Text] [Related]
5. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
7. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
8. VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription.
Singh PK; Long MD; Battaglia S; Hu Q; Liu S; Sucheston-Campbell LE; Campbell MJ
Epigenetics; 2015; 10(1):40-9. PubMed ID: 25494645
[TBL] [Abstract][Full Text] [Related]
9. Genomic and epigenomic active vitamin D responses in human colonic organoids.
Li J; Witonsky D; Sprague E; Alleyne D; Bielski MC; Lawrence KM; Kupfer SS
Physiol Genomics; 2021 Jun; 53(6):235-248. PubMed ID: 33900108
[TBL] [Abstract][Full Text] [Related]
10. Prostatic compensation of the vitamin D axis in African American men.
Richards Z; Batai K; Farhat R; Shah E; Makowski A; Gann PH; Kittles R; Nonn L
JCI Insight; 2017 Jan; 2(2):e91054. PubMed ID: 28138564
[No Abstract] [Full Text] [Related]
11. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
Kim S; Shevde NK; Pike JW
J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
[TBL] [Abstract][Full Text] [Related]
12. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor.
Dunlop TW; Väisänen S; Frank C; Molnár F; Sinkkonen L; Carlberg C
J Mol Biol; 2005 Jun; 349(2):248-60. PubMed ID: 15890193
[TBL] [Abstract][Full Text] [Related]
13. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1993 May; 132(5):1952-60. PubMed ID: 7682937
[TBL] [Abstract][Full Text] [Related]
16. Integrative genomic approaches to dissect clinically-significant relationships between the VDR cistrome and gene expression in primary colon cancer.
Long MD; Campbell MJ
J Steroid Biochem Mol Biol; 2017 Oct; 173():130-138. PubMed ID: 28027912
[TBL] [Abstract][Full Text] [Related]
17. The impact of chromatin organization of vitamin D target genes.
Carlberg C; Dunlop TW
Anticancer Res; 2006; 26(4A):2637-45. PubMed ID: 16886674
[TBL] [Abstract][Full Text] [Related]
18. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
19. Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns.
Doig CL; Singh PK; Dhiman VK; Thorne JL; Battaglia S; Sobolewski M; Maguire O; O'Neill LP; Turner BM; McCabe CJ; Smiraglia DJ; Campbell MJ
Carcinogenesis; 2013 Feb; 34(2):248-56. PubMed ID: 23087083
[TBL] [Abstract][Full Text] [Related]
20. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]